These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 32979280)

  • 1. Hematopoietic stem cell transplantation for diffuse large B-cell lymphoma having 8q24/MYC rearrangement in Japan.
    Takahashi T; Suzuki R; Yamamoto G; Nakazawa H; Kurosawa M; Kobayashi T; Okada M; Akasaka T; Kim SW; Fukuda T; Ichinohe T; Atsuta Y; Suzumiya J
    Hematol Oncol; 2021 Feb; 39(1):66-74. PubMed ID: 32979280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation.
    Herrera AF; Mei M; Low L; Kim HT; Griffin GK; Song JY; Merryman RW; Bedell V; Pak C; Sun H; Paris T; Stiller T; Brown JR; Budde LE; Chan WC; Chen R; Davids MS; Freedman AS; Fisher DC; Jacobsen ED; Jacobson CA; LaCasce AS; Murata-Collins J; Nademanee AP; Palmer JM; Pihan GA; Pillai R; Popplewell L; Siddiqi T; Sohani AR; Zain J; Rosen ST; Kwak LW; Weinstock DM; Forman SJ; Weisenburger DD; Kim Y; Rodig SJ; Krishnan A; Armand P
    J Clin Oncol; 2017 Jan; 35(1):24-31. PubMed ID: 28034071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes of allogeneic stem cell transplantation for DLBCL: a multi-center study from the Kyoto Stem Cell Transplantation Group.
    Izumi K; Kanda J; Nishikori M; Arai Y; Ishikawa T; Yoshioka S; Ueda Y; Maeda T; Yonezawa A; Anzai N; Moriguchi T; Imada K; Akasaka T; Nohgawa M; Itoh M; Aiba A; Tsunemine H; Watanabe M; Kondo T; Takaori-Kondo A
    Ann Hematol; 2019 Dec; 98(12):2815-2823. PubMed ID: 31713653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic impact of diffuse large B-cell lymphoma with extra copies of MYC, BCL2 and/or BCL6: comparison with double/triple hit lymphoma and double expressor lymphoma.
    Huang S; Nong L; Wang W; Liang L; Zheng Y; Liu J; Li D; Li X; Zhang B; Li T
    Diagn Pathol; 2019 Jul; 14(1):81. PubMed ID: 31315646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. C-MYC-positive relapsed and refractory, diffuse large B-cell lymphoma: Impact of additional "hits" and outcomes with subsequent therapy.
    Epperla N; Maddocks KJ; Salhab M; Chavez JC; Reddy N; Karmali R; Umyarova E; Bachanova V; Costa C; Glenn M; Calzada O; Xavier AC; Zhou Z; Hossain NM; Hernandez-Ilizaliturri FJ; Al-Mansour Z; Barta SK; Chhabra S; Lansigan F; Mehta A; Jaglal MV; Evens AM; Flowers CR; Cohen JB; Fenske TS; Hamadani M; Costa LJ
    Cancer; 2017 Nov; 123(22):4411-4418. PubMed ID: 28749548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation.
    Cuccuini W; Briere J; Mounier N; Voelker HU; Rosenwald A; Sundstrom C; Cogliatti S; Hirchaud E; Ysebaert L; Bron D; Soulier J; Gaulard P; Houlgatte R; Gisselbrecht C; Thieblemont C
    Blood; 2012 May; 119(20):4619-24. PubMed ID: 22408263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MYC single-hit large B-cell lymphoma: clinicopathologic difference from MYC-negative large B-cell lymphoma and MYC double-hit/triple-hit lymphoma.
    Cho YA; Hyeon J; Lee H; Cho J; Kim SJ; Kim WS; Ko YH
    Hum Pathol; 2021 Jul; 113():9-19. PubMed ID: 33771538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Significance of
    Ting CY; Chang KM; Kuan JW; Sathar J; Chew LP; Wong OJ; Yusuf Y; Wong L; Samsudin AT; Pana MNBM; Lee SK; Gopal NSR; Puri R; Ong TC; Bahari SK; Goh AS; Teoh CS
    Int J Med Sci; 2019; 16(4):556-566. PubMed ID: 31171907
    [No Abstract]   [Full Text] [Related]  

  • 9. Allogeneic hematopoietic stem cell transplantation in patients with diffuse large B cell lymphoma relapsed after autologous stem cell transplantation: a GITMO study.
    Rigacci L; Puccini B; Dodero A; Iacopino P; Castagna L; Bramanti S; Ciceri F; Fanin R; Rambaldi A; Falda M; Milone G; Guidi S; Martelli MF; Mazza P; Oneto R; Bosi A;
    Ann Hematol; 2012 Jun; 91(6):931-9. PubMed ID: 22245922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allogeneic stem cell transplantation in patients with de novo diffuse large B-cell lymphoma who experienced relapse or progression after autologous stem cell transplantation: a Korea-Japan collaborative study.
    Kim JW; Kim SW; Tada K; Fukuda T; Lee JH; Lee JJ; Kwon JH; Bang SM; Kim I; Yoon SS; Lee JS; Park S
    Ann Hematol; 2014 Aug; 93(8):1345-51. PubMed ID: 24633661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patterns of Utilization and Outcomes of Autologous Stem Cell Transplantation and Chimeric Antigen Receptor T-Cell Therapy in Relapsed or Refractory Diffuse Large B-cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements.
    Bliven SP; Shea L; Bal S; Goyal G; Mehta A; Narkhede M
    Clin Lymphoma Myeloma Leuk; 2022 Nov; 22(11):825-834. PubMed ID: 35869021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aggressive B cell Lymphoma: Optimal Therapy for MYC-positive, Double-Hit, and Triple-Hit DLBCL.
    Dunleavy K
    Curr Treat Options Oncol; 2015 Dec; 16(12):58. PubMed ID: 26634708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Upfront autologous hematopoietic stem cell transplantation for high-risk patients with double-expressor diffuse large B cell lymphoma.
    Kim YR; Yoon SO; Kim SJ; Cheong JW; Chung H; Lee JY; Jang JE; Kim Y; Yang WI; Min YH; Kim JS
    Ann Hematol; 2020 Sep; 99(9):2149-2157. PubMed ID: 32390113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical significance of 'double-hit' and 'double-expression' lymphomas.
    Ma Z; Niu J; Cao Y; Pang X; Cui W; Zhang W; Li X
    J Clin Pathol; 2020 Mar; 73(3):126-138. PubMed ID: 31615842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Cell of Origin Classification on Survival Outcomes after Autologous Transplantation in Relapsed/Refractory Diffuse Large B Cell Lymphoma.
    Joseph J; Ma J; Hennawy F; Abdulrazzaq MN; Saini N; Patel RD; Hosing CM; Alousi AM; Anderlini P; Popat UR; Qazilbash MH; Shpall EJ; Srour S; Kebriaei P; Bashir Q; Nastoupil LJ; Westin JR; Rondon G; Champlin RE; Andersson BS; Nieto Y; Muzzafar T; Ahmed S
    Transplant Cell Ther; 2021 May; 27(5):404.e1-404.e5. PubMed ID: 33965178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Double- or Triple-Hit Pathology on Rates and Durability of Radiation Therapy Response Among Patients With Relapsed or Refractory Large B-Cell Lymphoma.
    Kim A; Stevenson P; Cassaday RD; Soma L; Fromm JR; Gopal AK; Smith SD; Till B; Lynch RC; Ujjani C; Shadman M; Warren EH; Menon M; Russell K; Tseng YD
    Pract Radiat Oncol; 2020; 10(1):44-52. PubMed ID: 31585205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contribution of immunophenotype to the investigation and differential diagnosis of Burkitt lymphoma, double-hit high-grade B-cell lymphoma, and single-hit MYC-rearranged diffuse large B-cell lymphoma.
    Tsagarakis NJ; Papadhimitriou SI; Pavlidis D; Liapis K; Gortzolidis G; Kostopoulos IV; Marinakis T; Paterakis G
    Cytometry B Clin Cytom; 2020 Sep; 98(5):412-420. PubMed ID: 32497402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Survival Between Autologous and Allogeneic Stem Cell Transplantation in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: A Meta-Analysis.
    Wang J; Duan X; Yang L; Liu X; Hao C; Dong H; Gu H; Tang H; Dong B; Zhang T; Gao G; Liang R
    Cell Transplant; 2020; 29():963689720975397. PubMed ID: 33238731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic Significance of
    Rosenwald A; Bens S; Advani R; Barrans S; Copie-Bergman C; Elsensohn MH; Natkunam Y; Calaminici M; Sander B; Baia M; Smith A; Painter D; Pham L; Zhao S; Ziepert M; Jordanova ES; Molina TJ; Kersten MJ; Kimby E; Klapper W; Raemaekers J; Schmitz N; Jardin F; Stevens WBC; Hoster E; Hagenbeek A; Gribben JG; Siebert R; Gascoyne RD; Scott DW; Gaulard P; Salles G; Burton C; de Jong D; Sehn LH; Maucort-Boulch D
    J Clin Oncol; 2019 Dec; 37(35):3359-3368. PubMed ID: 31498031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MYC/BCL6 double-hit lymphoma (DHL): a tumour associated with an aggressive clinical course and poor prognosis.
    Li S; Desai P; Lin P; Yin CC; Tang G; Wang XJ; Konoplev SN; Khoury JD; Bueso-Ramos CE; Medeiros LJ
    Histopathology; 2016 Jun; 68(7):1090-8. PubMed ID: 26426741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.